Sale!

ELIGARD 30

LEUPROLIDE ACETATE INJECTABLE SUSPENSION 30MG

2-8* C
MRP : MRP 24,972.19
Price : 21,000.00
You Save : 3,972.19 (15.91%)

1 vial(s)

Buy Now
SKU: 051 Category: Tag: Brand:

Eligard Depot 30mg Injection contains the active substance Leuprolide acetate, which belongs to a group of medications known as gonadotropin-releasing hormone (GnRH) agonists. This injectable therapy is utilized in the management of hormone-sensitive conditions. In men, it is primarily prescribed to treat advanced prostate cancer. In women, it may be used for the treatment of hormone-responsive breast cancer, endometriosis (a condition where the uterine lining grows outside the uterus), and uterine fibroids (non-cancerous growths within the uterus). Additionally, this medication is also indicated for the treatment of precocious puberty, a disorder where children experience early onset of puberty due to hormonal imbalances.

You should not receive Eligard Depot 30mg if you are known to be allergic to this drug or any of its components, including similar agents such as Goserelin or Triptorelin. Prior to starting the treatment, inform your doctor if you suffer from any liver or kidney dysfunction, or if you have a history of abnormal uterine bleeding, especially if the cause is still undiagnosed. Women who are pregnant or planning to conceive should not use this medication, as it may harm the developing fetus. During the initial phase of therapy, some worsening of symptoms may occur due to a temporary surge in sex hormone levels—this is a known and expected effect of GnRH agonist therapy.

It is also important to inform your healthcare provider about any pre-existing medical conditions, such as diabetes, seizure disorders, cardiovascular diseases (including angina or irregular heartbeats), depression, or if you have an increased risk of osteoporosis (bone thinning). This medication is not suitable for patients experiencing unexplained or abnormal vaginal bleeding.

If you are a woman of childbearing age, you should use non-hormonal methods of contraception throughout the treatment duration. Male patients should report any history of urinary obstruction, spinal cord compression, previous orchiectomy (surgical removal of the testicles), or symptoms such as difficulty urinating or blood in the urine (haematuria). Children receiving this treatment should also be monitored closely, and any signs of a progressive brain tumor must be reported to the doctor immediately.